JEREMY RINALDI: Open Payments
NPI 1114574159 · SAN LUIS OBISPO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,066 in 56 payments from 12 companies in 2025. Trend: 2023 $320 · 2024 $824 · 2025 $1,066
Food & beverage: $977Education: $89
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $247 |
| GlaxoSmithKline, LLC. | 18 | $191 |
| BioCryst US Sales Co., LLC | 8 | $183 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $96 |
| Ionis Pharmaceuticals, Inc. | 3 | $70 |
| Novartis Pharmaceuticals Corporation | 3 | $64 |
| Genentech USA, Inc. | 2 | $59 |
| AstraZeneca Pharmaceuticals LP | 2 | $48 |
| ALK-Abello, Inc | 2 | $47 |
| CSL Behring | 1 | $23 |
Products named: DUPIXENT, ORLADEYO, NUCALA, NEFFY, TRELEGY ELLIPTA, Xolair, TEZSPIRE, Odactra.
Industry payments across CA — which companies pay providers there.
